Tags

Type your tag names separated by a space and hit enter

Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics.

Abstract

Psoriasis is a common, chronic, inflammatory, multisystem disease with predominantly skin and joint manifestations affecting approximately 2% of the population. In this first of 5 sections of the guidelines of care for psoriasis, we discuss the classification of psoriasis; associated comorbidities including autoimmune diseases, cardiovascular risk, psychiatric/psychologic issues, and cancer risk; along with assessment tools for skin disease and quality-of-life issues. Finally, we will discuss the safety and efficacy of the biologic treatments used to treat patients with psoriasis.

Links

  • Publisher Full Text
  • Authors+Show Affiliations

    ,

    Baylor University Medical Center, Dallas, Texas, USA.

    , , , , , , , , , ,

    Source

    MeSH

    Acitretin
    Alefacept
    Antibodies, Monoclonal
    Arthritis, Psoriatic
    Biological Products
    Cardiovascular Diseases
    Cyclosporine
    Depression
    Etanercept
    Humans
    Immunoglobulin G
    Interleukin-12
    Interleukin-23
    Lymphoma
    Metabolic Syndrome
    Methotrexate
    Obesity
    PUVA Therapy
    Psoriasis
    Receptors, Tumor Necrosis Factor
    Recombinant Fusion Proteins
    Smoking
    Tumor Necrosis Factor-alpha

    Pub Type(s)

    Consensus Development Conference
    Journal Article
    Practice Guideline

    Language

    eng

    PubMed ID

    18423260

    Citation

    Menter, Alan, et al. "Guidelines of Care for the Management of Psoriasis and Psoriatic Arthritis: Section 1. Overview of Psoriasis and Guidelines of Care for the Treatment of Psoriasis With Biologics." Journal of the American Academy of Dermatology, vol. 58, no. 5, 2008, pp. 826-50.
    Menter A, Gottlieb A, Feldman SR, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol. 2008;58(5):826-50.
    Menter, A., Gottlieb, A., Feldman, S. R., Van Voorhees, A. S., Leonardi, C. L., Gordon, K. B., ... Bhushan, R. (2008). Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. Journal of the American Academy of Dermatology, 58(5), pp. 826-50. doi:10.1016/j.jaad.2008.02.039.
    Menter A, et al. Guidelines of Care for the Management of Psoriasis and Psoriatic Arthritis: Section 1. Overview of Psoriasis and Guidelines of Care for the Treatment of Psoriasis With Biologics. J Am Acad Dermatol. 2008;58(5):826-50. PubMed PMID: 18423260.
    * Article titles in AMA citation format should be in sentence-case
    TY - JOUR T1 - Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. AU - Menter,Alan, AU - Gottlieb,Alice, AU - Feldman,Steven R, AU - Van Voorhees,Abby S, AU - Leonardi,Craig L, AU - Gordon,Kenneth B, AU - Lebwohl,Mark, AU - Koo,John Y M, AU - Elmets,Craig A, AU - Korman,Neil J, AU - Beutner,Karl R, AU - Bhushan,Reva, PY - 2008/02/27/received PY - 2008/02/27/revised PY - 2008/02/28/accepted PY - 2008/4/22/pubmed PY - 2008/5/8/medline PY - 2008/4/22/entrez SP - 826 EP - 50 JF - Journal of the American Academy of Dermatology JO - J. Am. Acad. Dermatol. VL - 58 IS - 5 N2 - Psoriasis is a common, chronic, inflammatory, multisystem disease with predominantly skin and joint manifestations affecting approximately 2% of the population. In this first of 5 sections of the guidelines of care for psoriasis, we discuss the classification of psoriasis; associated comorbidities including autoimmune diseases, cardiovascular risk, psychiatric/psychologic issues, and cancer risk; along with assessment tools for skin disease and quality-of-life issues. Finally, we will discuss the safety and efficacy of the biologic treatments used to treat patients with psoriasis. SN - 1097-6787 UR - https://www.unboundmedicine.com/medline/citation/18423260/full_citation L2 - https://linkinghub.elsevier.com/retrieve/pii/S0190-9622(08)00273-9 DB - PRIME DP - Unbound Medicine ER -